Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,300	Closed	-$4.6K	–	13984
2025 Q1	$4.6K	Buy	1,300 +700	+117%	+$2.9K	﹤0.01%	13880
2024 Q4	$1.91K	Sell	600 -5,500	-90%	-$18.8K	﹤0.01%	14131
2024 Q3	$22.4K	Buy	6,100 +500	+9%	+$2.06K	﹤0.01%	12699
2024 Q2	$26.2K	Sell	5,600 -2,800	-33%	-$16.8K	﹤0.01%	12401
2024 Q1	$73.9K	Buy	8,400 +8,000	+2,000%	+$42.7K	﹤0.01%	11750
2023 Q4	$1.71K	Sell	400 -6,400	-94%	-$22.6K	﹤0.01%	13784
2023 Q3	$23.2K	Buy	6,800 +6,600	+3,300%	+$30K	﹤0.01%	12504
2023 Q2	$1.13K	Sell	200 -200	-50%	-$1.03K	﹤0.01%	13983
2023 Q1	$1.93K	Hold	400	–	–	﹤0.01%	14231
2022 Q4	$2.42K	Sell	400 -14,100	-97%	-$70.6K	﹤0.01%	14341
2022 Q3	$69K	Buy	+14,500	New	+$77.9K	﹤0.01%	11405

Other funds holding LTRN

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q1 2026 in Review

Citadel Advisors sold out of Lantern Pharma (LTRN) in Q1 2026, closing a stake of 32,895 shares — an estimated $99.7K sold.

Citadel Advisors first reported a position in LTRN in Q1 2021 and held it in 11 quarters. The position peaked at $203K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

Citadel Advisors reported no remaining Lantern Pharma position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 32,895 Lantern Pharma shares in Q1 2026, an estimated $99.7K.
Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and held it in 11 quarters.
Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.